The lupus nephritis treatment market is anticipated to develop at a compound annual growth rate (CAGR) of 11% from 2023 to 2033, from its present value of US$ 1.8 billion in 2022 to US$ 5.67 billion by 2033. The rise in the market can be attributed to several factors, including the rising incidence of the condition, more public awareness, and the introduction of novel, state-of-the-art treatments. The market for lupus nephritis treatments grew historically at a CAGR of 6.5% between 2018 and 2022.
Like
Comment
Share
